亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 in subjects with inoperable locally advanced or metastatic solid tumors (301)

医学 耐受性 肿瘤科 药代动力学 内科学 实体瘤疗效评价标准 宫颈癌 放射免疫疗法 卵巢癌 抗体-药物偶联物 免疫原性 癌症 不利影响 临床试验 抗体 单克隆抗体 临床研究阶段 免疫学
作者
Anthony W. Tolcher,Andrae Vandross,Melissa M. Johnson,Haeseong Park,Christian Scheffold,Jing Li,Neby Bekele,Shailaja Uttamsingh,Raffaella Faggioni,Susanna V. Ulahannan
出处
期刊:Gynecologic Oncology [Elsevier]
卷期号:166: S158-S158
标识
DOI:10.1016/s0090-8258(22)01523-2
摘要

Objectives: Cervical cancer and epithelial ovarian cancer (EOC) are two of the most prevalent gynecologic cancers associated with high mortality. Despite recent advancements in therapy, there is an unmet need for novel treatments to improve survival outcomes. XB002 is an antibody-drug conjugate (ADC) that targets tissue factor (TF). TF is a protein overexpressed in many solid tumors, including gynecologic cancers, and is associated with disease progression and poor prognosis. XB002 is a human mAb (25A3) directed against TF conjugated to a novel cytotoxic agent (payload) N-acyl sulfonamide auristatin, ZD02044. XB002 has been designed to improve the therapeutic potential of ADCs targeting TF as a new therapeutic strategy in cancers. XB002 has demonstrated activity in several solid tumor xenograft models. The objective of this ongoing first-in-human study is to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity (anti-drug antibodies [ADA]), and preliminary antitumor activity of XB002 in patients with advanced solid tumors with limited treatment options. Presented here are the trial design and details of the cervical and EOC cohorts. Methods: In this phase 1, non-randomized, open-label, multicenter, dose-escalation, and dose-expansion study (NCT04925284), patients with advanced solid tumors will receive XB002 IV every three weeks at a starting dose of 0.16 mg/kg. In the dose-escalation stage, an i3+3 study design will be used to identify the maximum tolerated dose (MTD)/recommended dose (RD) and/or the maximum allowed dose of XB002. Dose level decisions will be made by the Cohort Review Committee after review of all available safety and PK data. In the cohort-expansion phase, the MTD/RD will be further evaluated for safety and preliminary efficacy in multiple tumor-specific expansion cohorts that will be enrolled using a Simon's 2-stage design. Patients will be treated until radiographic progression per RECIST v1.1 or unacceptable toxicity. Patients in the cervical and EOC expansion cohorts must have received ≤2 (cervical) or ≤3 (EOC) lines of prior systemic anticancer therapy for locally advanced or metastatic disease. Patients must have received prior platinum-containing therapy in both cohorts, and patients must have platinum-resistant disease in the EOC cohort. The primary endpoint of the cohort-expansion stage will be objective response rate (ORR) per RECIST v1.1 assessed by the investigator. Other endpoints will include duration of response (DOR) and progression-free survival (PFS) per RECIST v1.1 assessed by the investigator, and overall survival; ORR, DOR, and PFS may also be assessed by a blinded independent radiology committee in select expansion cohorts. The effects of XB002 on tumor and blood biomarkers, including TF expression, will be assessed in exploratory analyses. For patients with EOC, blood samples for CA125 assessment will be collected at screening and throughout treatment in both stages of the study.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
hyhyhyhy发布了新的文献求助10
4秒前
星辰大海应助粽子采纳,获得10
25秒前
烟花应助基围虾采纳,获得10
26秒前
小葡萄完成签到,获得积分10
32秒前
派大星发布了新的文献求助30
36秒前
38秒前
LEESO发布了新的文献求助10
44秒前
科研通AI2S应助科研通管家采纳,获得10
51秒前
LEESO完成签到,获得积分10
51秒前
51秒前
52秒前
三叔发布了新的文献求助10
58秒前
1分钟前
三叔完成签到,获得积分0
1分钟前
1分钟前
基围虾发布了新的文献求助10
1分钟前
打打应助燕海雪采纳,获得10
1分钟前
1分钟前
粽子发布了新的文献求助10
1分钟前
顺利山柏完成签到 ,获得积分10
1分钟前
无花果应助lixiaojin采纳,获得10
1分钟前
zpli完成签到 ,获得积分10
2分钟前
Nefelibata完成签到,获得积分10
2分钟前
2分钟前
lixiaojin发布了新的文献求助10
2分钟前
俭朴夜雪完成签到,获得积分10
2分钟前
Limerencia完成签到,获得积分10
2分钟前
lixiaojin完成签到,获得积分10
2分钟前
打打应助wyg1994采纳,获得10
2分钟前
烟花应助基围虾采纳,获得10
2分钟前
下午好完成签到 ,获得积分10
2分钟前
gc完成签到 ,获得积分10
2分钟前
2分钟前
2分钟前
八月发布了新的文献求助30
2分钟前
今后应助科研通管家采纳,获得10
2分钟前
丘比特应助科研通管家采纳,获得10
2分钟前
3分钟前
基围虾发布了新的文献求助10
3分钟前
吴嘉俊完成签到 ,获得积分10
3分钟前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Le dégorgement réflexe des Acridiens 800
Defense against predation 800
Very-high-order BVD Schemes Using β-variable THINC Method 568
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3137011
求助须知:如何正确求助?哪些是违规求助? 2787960
关于积分的说明 7784062
捐赠科研通 2444016
什么是DOI,文献DOI怎么找? 1299609
科研通“疑难数据库(出版商)”最低求助积分说明 625497
版权声明 600989